G

Genedrive PLC
LSE:GDR

Watchlist Manager
Genedrive PLC
LSE:GDR
Watchlist
Price: 2.4 GBX -2.04% Market Closed
Market Cap: 13m GBX
Have any thoughts about
Genedrive PLC?
Write Note

Genedrive PLC
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genedrive PLC
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
G
Genedrive PLC
LSE:GDR
Additional Paid In Capital
ÂŁ54.3m
CAGR 3-Years
N/A
CAGR 5-Years
13%
CAGR 10-Years
11%
Oxford Nanopore Technologies PLC
LSE:ONT
Additional Paid In Capital
ÂŁ698.6m
CAGR 3-Years
5%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Additional Paid In Capital
ÂŁ37.1m
CAGR 3-Years
0%
CAGR 5-Years
227%
CAGR 10-Years
N/A
Ergomed PLC
LSE:ERGO
Additional Paid In Capital
ÂŁ1m
CAGR 3-Years
-67%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Additional Paid In Capital
ÂŁ58.5m
CAGR 3-Years
3%
CAGR 5-Years
13%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Additional Paid In Capital
ÂŁ516k
CAGR 3-Years
N/A
CAGR 5-Years
-49%
CAGR 10-Years
-19%
No Stocks Found

Genedrive PLC
Glance View

Market Cap
13m GBX
Industry
Life Sciences Tools & Services

Genedrive Plc is a holding company, which engages in the development of drugs and disease diagnostics. The Company’s Genedrive device is a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company’s commercial products include Genedrive MT-RNR1, Genedrive BioPlex, Genedrive HCV ID Kit and Genedrive 96 SARS-CoV-2 Ki. Genedrive MT-RNR1 is a commercial test for antibiotic induced hearing loss. Genedrive BioPlex is developed for the determination of military biothreats from pathogens. Genedrive HCV ID Kit is effective in the diagnosis of Hepatitis C Virus (HCV) infection in resource limited settings. Genedrive 96 SARS-CoV-2 Ki is a plate format of a COVID-19 molecular test for high throughput use, which detects all known variants of COVID-19.

GDR Intrinsic Value
0.41 GBX
Overvaluation 83%
Intrinsic Value
Price
G

See Also

What is Genedrive PLC's Additional Paid In Capital?
Additional Paid In Capital
54.3m GBP

Based on the financial report for Dec 31, 2023, Genedrive PLC's Additional Paid In Capital amounts to 54.3m GBP.

What is Genedrive PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
11%

Over the last year, the Additional Paid In Capital growth was 3%.

Back to Top